Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its in-house developed bispecific antibody drug conjugate (ADC), BL-M17D1, in patients with advanced solid tumors.
BL-M17D1’s Development and Mechanism
BL-M17D1 is a novel ADC that shares similarities with Biokin’s another ADC drug, BL-B16D1. Both drugs are derived from the company’s small molecule technology platform and utilize the “linker+toxin” platform. According to Fineline Info & Tech data, BL-M17D1 targets the HER2 antigen, which is overexpressed in various types of cancers, making it a promising candidate for cancer treatment.
Clinical Trial Significance
The approval to proceed with a Phase I clinical study is a significant milestone for Sichuan Biokin Pharmaceutical. It marks the company’s progress in developing innovative cancer therapies and highlights the potential of BL-M17D1 as a new treatment option for patients with advanced solid tumors.-Fineline Info & Tech
Leave a Reply